Barclays PLC Arvinas, Inc. Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Barclays PLC holds 40,715 shares of ARVN stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,715

Previous 55,474 26.61%

Holding current value

$1.1 Million

Previous $2.29 Million 52.64%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$24.46 - $40.4 $361,005 - $596,263	-14,759 Reduced 26.61%	40,715 $1.09 Million
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $1.02 Million - $1.47 Million	-28,147 Reduced 33.66%	55,474 $2.29 Million
Q4 2023 Feb 15, 2024	BUY	$14.19 - $42.33 $707,002 - $2.11 Million	49,824 Added 147.42%	83,621 $3.44 Million
Q3 2023 Nov 07, 2023	BUY	$19.64 - $28.21 $141,957 - $203,901	7,228 Added 27.2%	33,797 $663,000
Q2 2023 Aug 03, 2023	SELL	$21.73 - $31.43 $168,885 - $244,273	-7,772 Reduced 22.63%	26,569 $658,000
Q1 2023 May 04, 2023	BUY	$26.15 - $37.26 $291,781 - $415,747	11,158 Added 48.13%	34,341 $937,000
Q4 2022 Feb 13, 2023	SELL	$32.47 - $57.24 $441,364 - $778,063	-13,593 Reduced 36.96%	23,183 $793,000
Q3 2022 Nov 03, 2022	BUY	$41.87 - $57.99 $669,291 - $926,970	15,985 Added 76.88%	36,776 $1.64 Million
Q2 2022 Aug 12, 2022	SELL	$36.01 - $74.24 $7.28 Million - $15 Million	-202,103 Reduced 90.67%	20,791 $875,000
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $5.3 Million - $7.17 Million	-87,927 Reduced 28.29%	222,894 $15 Million
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $568,417 - $830,484	8,632 Added 2.86%	310,821 $25.5 Million
Q3 2021 Nov 09, 2021	BUY	$73.2 - $107.87 $4.3 Million - $6.33 Million	58,711 Added 24.11%	302,189 $24.8 Million
Q2 2021 Aug 13, 2021	SELL	$60.45 - $84.26 $1.76 Million - $2.46 Million	-29,154 Reduced 10.69%	243,478 $18.7 Million
Q1 2021 May 13, 2021	BUY	$58.19 - $91.37 $1.33 Million - $2.08 Million	22,787 Added 9.12%	272,632 $18 Million
Q4 2020 Feb 11, 2021	BUY	$20.19 - $84.93 $1.57 Million - $6.62 Million	77,973 Added 45.37%	249,845 $21.2 Million
Q3 2020 Nov 12, 2020	BUY	$22.99 - $36.34 $1.03 Million - $1.63 Million	44,718 Added 35.17%	171,872 $4.06 Million
Q2 2020 Aug 12, 2020	BUY	$29.88 - $56.74 $1.16 Million - $2.21 Million	38,906 Added 44.09%	127,154 $4.27 Million
Q1 2020 May 13, 2020	BUY	$33.0 - $54.5 $661,980 - $1.09 Million	20,060 Added 29.42%	88,248 $3.56 Million
Q4 2019 Feb 10, 2020	SELL	$15.39 - $44.38 $317,526 - $915,648	-20,632 Reduced 23.23%	68,188 $2.8 Million
Q3 2019 Nov 14, 2019	BUY	$21.55 - $27.61 $1.63 Million - $2.09 Million	75,733 Added 578.69%	88,820 $1.91 Million
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $30,802 - $45,934	1,930 Added 17.3%	13,087 $288,000
Q1 2019 May 15, 2019	BUY	$13.55 - $23.79 $151,177 - $265,425	11,157 New	11,157 $165,000
Q4 2018 Feb 14, 2019	SELL	$11.19 - $18.56 $111,900 - $185,600	-10,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$16.05 - $16.87 $160,500 - $168,700	10,000 New	10,000 $169,000

Others Institutions Holding ARVN

# of Institutions

222

Shares Held

68.8M

Call Options Held

166K

Put Options Held

31.3K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.44B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account